Evidence map›Paper›PMID 40765762›Full record

ReviewInternational journal of molecular and cellular medicine2025

Navigating the Molecular Signaling: Deciphering Cancer Stem Cell Self-Renewal Pathways.

Seyed Nasser Hoseinian, Mohammad Saeedi, Mohammad Erfan Saravani, Sepideh Zenoozi, Fatemeh Mehranfar, Amin Pouyan

Abstract readReview
In one paragraph

Review in International journal of molecular and cellular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Seyed Nasser HoseinianDepartment of Hematology, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohammad SaeediDepartment of Laboratory Science, Faculty of medicine, Semnan University of Medical Sciences, Semnan, Iran.
Mohammad Erfan SaravaniDepartment of Laboratory Sciences, Sabzevar University of Medical Sciences, Sabzevar, Iran.
Sepideh ZenooziDepartment of Occupational Therapy, School of Health Professions, University of Missouri, Columbia, Missouri, USA.
Fatemeh MehranfarDepartment of Laboratory Science, Faculty of medicine, Semnan University of Medical Sciences, Semnan, Iran.
Amin PouyanDepartment of Laboratory Science, Faculty of medicine, Semnan University of Medical Sciences, Semnan, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer stem cells (CSCs) are a subset of cells within tumors that exhibit stem cell-like characteristics, including the ability to self-renew and differentiate. CSCs are the cause of carcinogenesis and tumorigenesis. The expression of cell surface markers, which varies linked to the kind of tumor, is utilized to recognize CSCs. An essential part of tumor invasion and metastasis is played by CSCs. Numerous investigations have been carried out to find distinguished markers and different phenotypes of CSCs, which are especially crucial for identifying and separating this subset of cells. It was discovered that the regulation of CSCs involves a multitude of signaling pathways. These cells are determined by their ability to self-renewal pathways such as Wnt/β-catenin, JAK/STAT3, PTEN/PI3-K/Akt, and Hedgehog, their surface biomarkers, and their resistance to many drugs. Aberrant activation of these signaling pathways is associated with cell growth. Thus, focusing on CSCs is seen to be a viable anti-cancer treatment approach. It is encouraging that CSCs' self-renewal pathways present a viable target for changing their survival tactics and limiting their capacity to proliferate tumors. This study highlights the characterization and investigation of CSC self-renewal pathways, also discusses potential targeted therapy for CSC, and gives a summary of the significant factors and pathways that adjust CSC formation.

Indexed as

Cancer Stem cellsMolecular SignalingSelf-renewaltargeted therapyTumor recurrence

Identifiers

PMID40765762
PMCPMC12321308

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.